Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
Healthcare giant Eli Lilly’s Phase III EMBER-3 study in patients with advanced breast cancer showed imlunestrant, cut the risk of disease progression or death by 38% - but only a subset of ...
GlobalData on MSN14d
Lilly gains US FDA approval for Omvoh to treat Crohn’s diseaseEli Lilly has received approval from the US Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz) to treat moderately to severely active Crohn's disease in the adult population. This is the ...
In the pivotal trial, patients treated with Omvoh experienced significant improvements in clinical remission and endoscopic ...
FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
14d
Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback